Information Provided By: 
Fly News Breaks for February 28, 2017
PODD
Feb 28, 2017 | 08:33 EDT
Baird analyst Jeff Johnson said Insulet posted solid Q4 results and as a result sees the weakness following the results a s buying opportunity. Johnson cited the better than expected revenues from its U.S. Omnipod and drug delivery. Johnson also noted the company's growing pipeline. Johnson reiterated his Outperform rating and raised his price target to $49 from $47 on Insulet shares.
News For PODD From the Last 2 Days
There are no results for your query PODD
